drugset / Trial / NCT04850339
First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers
RandomizedSequentialQuadruple-blindTreatment
Summary
This is an adaptive, randomised, double-blind, single-centre, placebo-controlled phase I, First in Human study designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous dosing of ANXV in healthy male subjects.
Timeline
- Start
- 2020-12-21
- Primary completion
- 2021-10-27
- Completion
- 2021-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Recombinant Human Annexin A5 | Protein / enzyme biologic | — | Intravenous |
Indications
No indication recorded.